Anlon Healthcare Announces Financial Results for FY 2026; Details Deviation in Use of IPO Proceeds
Anlon Healthcare Limited, a research-intensive manufacturer of Active Pharmaceutical Ingredients (APIs) and drug intermediates, announced its audited financial results for the financial year ending March 31, 2026, on May 29, 2026. The company also provided details regarding the utilization of its issue proceeds.The financial results for the Standalone and Consolidated accounts were reviewed and approved by the Board of Directors during a meeting held on May 29, 2026.
Financial Highlights for FY 2026
The company's financial results show significant figures across its operational segments. The reported financial information includes results for the quarter ended March 31, 2026, which represent balancing figures between the audited full-year figures and unaudited year-to-date figures up to the third quarter.Standalone Performance
The Standalone Balance Sheet as of March 31, 2026, reflects a total asset base of 31,720.50 Rs. in Lacs.| Particulars | As at 31-03-2026 (Rs. in Lacs) | As at 31-03-2025 (Rs. in Lacs) |
|---|---|---|
| Total Assets | 31,720.50 | 18,130.00 |
| Total Equity | 20,977.27 | 8,042.17 |
| Total Current Assets | 25,973.09 | 15,848.10 |
The Standalone Cash Flow Statement for the period ended March 31, 2026, reported a Net cash generated by operating activities of 4,635.81 Rs. in Lacs, compared to 2,255.18 Rs. in Lacs for the previous year.
Consolidated Group Performance
The Consolidated Balance Sheet as of March 31, 2026, indicates a substantial growth in the Group's total assets, reaching 37,396.51 Rs. in Lacs, up from 18,130.00 Rs. in Lacs at the same date in the previous year.| Particulars | As at 31-03-2026 (Rs. in Lacs) | As at 31-03-2025 (Rs. in Lacs) |
|---|---|---|
| Total Assets | 37,396.51 | 18,130.00 |
| Total Equity | 23,022.86 | 8,042.17 |
| Total Current Assets | 30,826.03 | 15,848.10 |
The Consolidated Cash Flow Statement also reported a Net cash generated by operating activities of 7,944.00 Rs. in Lacs for the year ended March 31, 2026.
Audit and Fund Utilization Status
The statutory auditors have issued an Audit Report confirming that the Standalone Annual Financial Results and the Consolidated Annual Financial Results for the year ended March 31, 2026, give a true and fair view in conformity with applicable accounting standards. The opinion for both standalone and consolidated results was unmodified.Regarding the utilization of the initial public offering (IPO) proceeds, Anlon Healthcare Limited reported a deviation/variation in the usage of funds.
The company received shareholder approval on January 7, 2026, to vary the objects of the IPO. The initial amount raised was Rs. 12,103.00 Lacs. The variation proposes the deployment and utilization of Rs. 2,332.69 lakhs out of the original Rs. 3,071.95 lakhs.
Company Overview
Anlon Healthcare Limited is situated in Rajkot, India. It is a publicly listed, research-intensive manufacturing company specializing in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates, maintaining global recognition for high-quality pharmaceutical bulk drugs. The equity shares are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the Bombay Stock Exchange (BSE) under the code 544497.AHCL Stock Price Movement
Anlon Healthcare Limited shares today slipped by 2.81% to settle at ₹13.85 in post-market trading. The stock saw significant activity, trading on a total volume of 10.07 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: